GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » EV-to-EBITDA

EV Biologics (EV Biologics) EV-to-EBITDA : -4.06 (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EV Biologics's enterprise value is $5.87 Mil. EV Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was $-1.45 Mil. Therefore, EV Biologics's EV-to-EBITDA for today is -4.06.

The historical rank and industry rank for EV Biologics's EV-to-EBITDA or its related term are showing as below:

YECO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.06   Med: 0   Max: 0
Current: -4.06

YECO's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 10.52 vs YECO: -4.06

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), EV Biologics's stock price is $0.5541. EV Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was $-3.550. Therefore, EV Biologics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


EV Biologics EV-to-EBITDA Historical Data

The historical data trend for EV Biologics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics EV-to-EBITDA Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
EV-to-EBITDA
- - 4.54 -0.59 -0.29

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -0.65 -0.16 -0.29 -10.31

Competitive Comparison of EV Biologics's EV-to-EBITDA

For the Biotechnology subindustry, EV Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where EV Biologics's EV-to-EBITDA falls into.



EV Biologics EV-to-EBITDA Calculation

EV Biologics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5.870/-1.445
=-4.06

EV Biologics's current Enterprise Value is $5.87 Mil.
EV Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

EV Biologics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.5541/-3.550
=At Loss

EV Biologics's share price for today is $0.5541.
EV Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.550.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


EV Biologics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of EV Biologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics Updates on Funding and Sales

By ACCESSWIRE 10-02-2023

EV Biologics Updates on FINRA Filings

By ACCESSWIRE ACCESSWIRE 03-09-2022

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021